PYPD

PolyPid Ltd. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website olypid.com
Employees(FY) -
ISIN IL0011326795

Performance

-0.29%

-2.79%

-1.69%

-19.12%

-8.16%

YTD

-14.25%

Profile

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Advanced Technical Analysis

Technical Analysis of PYPD 2024-11-20

The Moving Average Score of 63 indicates a bullish sentiment, while the Oscillators Score of 46 and the Technical Score of 55 suggest a more neutral outlook. Overall, the combined scores reflect a cautiously optimistic sentiment in the stock, driven primarily by the strong moving average performance.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PYPD

Stock Rank

Recent News & Updates

2024-11-13 13:08
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges(Yahoo Finance)
2024-11-12 18:00
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-11-06 18:00
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference(Globenewswire)
2024-10-29 20:00
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024(Globenewswire)
2024-10-23 07:01
Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd(Yahoo Finance)
2024-10-20 19:00
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery(Globenewswire)
2024-09-30 19:00
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections(Globenewswire)
2024-09-02 19:00
PolyPid to Participate in Three Upcoming Fall Investor Conferences(Globenewswire)
2024-08-13 19:00
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results(Globenewswire)
2024-08-01 08:31
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds(Globenewswire)
2024-07-30 19:00
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024(Globenewswire)
2024-06-17 19:00
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial(Globenewswire)
2024-06-09 19:00
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX100 Phase 3 Trial(Globenewswire)
2024-05-10 05:25
PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-07 23:56
PYPD Stock Earnings: PolyPid Beats EPS for Q1 2024(Investorplace)
2024-05-07 19:00
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results(Globenewswire)
2024-04-30 19:00
PolyPid to Participate in Citizens JMP Life Sciences Conference(Globenewswire)
2024-04-29 19:00
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections(Globenewswire)
2024-04-23 19:00
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024(Globenewswire)
2024-02-27 18:00
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference(Globenewswire)
2024-02-18 23:00
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?(Zacks)
2024-02-14 20:41
PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-02-13 18:00
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results(Globenewswire)
2024-02-11 18:00
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial(Globenewswire)
2024-01-30 18:00
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024(Globenewswire)
2024-01-04 03:32
PolyPid Announces Private Placement for $16 Million in Gross Proceeds(Globenewswire)
2023-11-11 21:40
PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript(Yahoo Finance)
2023-11-07 18:00
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results(Globenewswire)
2023-11-06 18:00
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors(Globenewswire)
2023-10-31 19:00
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.